This article is more than 5 years old. Information may no longer be current.
Ionis licenses locally acting, oral antisense GI drug to Janssen
Click Here to Manage Email Alerts
Ionis Pharmaceuticals has licensed IONIS-JBI1-2.5Rx to Janssen Biotech for $10 million. The agent is an oral antisense drug intended to locally inhibit an unspecified GI tract target to treat a GI autoimmune disease, according to a press release.
“IONIS-JBI1-2.5Rx is the first antisense drug to enter development as part of Ionis’ collaboration with Janssen to discover and develop orally administered, locally acting RNA-targeted therapeutics for autoimmune diseases in the gastrointestinal tract,” B. Lynne Parshall, chief operating officer at Ionis Pharmaceuticals, said in the press release. “We are very pleased to have rapidly advanced this first drug candidate into development within a year and a half of initiating our collaboration with Janssen. This new drug further expands our technology’s reach into a new therapeutic setting and a new route of delivery.”
The agreement covers three programs, and under the terms Ionis may receive almost $800 million in development, regulatory and sales milestone payments and license fees, as well as tiered royalties on successfully commercialized products. Janssen will assume responsibility for global development, regulation and commercialization after IND-enabling studies are completed, according to the press release.
Disclosures: Parshall is employed by Ionis Pharmaceuticals.